A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-07 and is reviewed periodically as new material appears.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
=== Radiation protection register === According to § 170 StrlSchG [Radiation Protection Act] (in German) all occupationally exposed persons and holders of radiation passports require a radiation protection register number (SSR number or SSRN), a unique personal identification number, as of December 31, 2018. The SSR number facilitates and improves the allocation and balancing of individual dose values from occupational radiation exposure in the radiation protection register. It replaces the former radiation passport number. It is used to monitor dose limits. Companies are obliged to deploy their employees in such a way that the radiation dose to which they are exposed does not exceed the limit of 20 millisieverts per calendar year. In Germany, about 440,000 people were classified as occupationally exposed to radiation in 2016. According to § 145 StrlSchG [German Radiation Protection Act] (in German) paragraph 1, Sentence 1, "in the case of remediation and other measures to prevent and reduce exposure at radioactively contaminated sites, the person who carries out the measures himself or has them carried out by workers under his supervision must carry out an assessment of the body dose of the workers before starting the measures". Applications for SSR numbers must be submitted to the Federal Office for Radiation Protection (BfS) by March 31, 2019 for all employees currently under surveillance.
=== Cushing's Disease === Corticotropic cells can have detrimental effects on the body if they express too much or too little ACTH. One such example is Cushing's disease, which can result from overproduction of ACTH in the corticotropes due to pituitary tumors known as corticotroph adenomas; this is the cause for roughly two-thirds of those diagnosed with Cushing's disease. It is also possible that this disease can result from production of ACTH in a non-pituitary tumor, known as ectopic production, or the adrenal glands can overproduce cortisol due to an adrenal tumor. This overproduction of ACTH causes an increase in cortisol levels due to increased glucocorticoid synthesis in the adrenal cortex resulting in several associated symptoms. Symptoms of Cushing's disease include:
== Mechanism == Biochemical and structural analyses of aminopeptidase (APPro), methionine aminopeptidase (MetAP), and prolidase, all members of the "pita-bread" metalloenzymes, suggest that they share a common mechanism scheme. The main difference arises in the location of the carbonyl oxygen atom of the scissile peptide bond.
=== Legal status === In the United States, benzodiazepines are Schedule IV drugs under the Federal Controlled Substances Act, even when not on the market (for example, flunitrazepam), with the exception of flualprazolam, etizolam, clonazolam, flubromazolam, and diclazepam which are placed in Schedule I. In Canada, possession of benzodiazepines is legal for personal use. All benzodiazepines are categorized as Schedule IV substances under the Controlled Drugs and Substances Act. In the United Kingdom, benzodiazepines are Class C controlled drugs, carrying the maximum penalty of 7 years imprisonment, an unlimited fine, or both for possession and a maximum penalty of 14 years imprisonment, an unlimited fine, or both for supplying benzodiazepines to others. In the Netherlands, since October 1993, benzodiazepines, including formulations containing less than 20 mg of temazepam, are all placed on List 2 of the Opium Law. A prescription is needed for possession of all benzodiazepines. Temazepam formulations containing 20 mg or greater of the drug are placed on List 1, thus requiring doctors to write prescriptions in the List 1 format. In East Asia and Southeast Asia, temazepam and nimetazepam are often heavily controlled and restricted. In certain countries, triazolam, flunitrazepam, flutoprazepam and midazolam are also restricted or controlled to certain degrees. In Hong Kong, all benzodiazepines are regulated under Schedule 1 of Hong Kong's Chapter 134 Dangerous Drugs Ordinance. Previously only brotizolam, flunitrazepam and triazolam were classed as dangerous drugs.
Teprotumumab, sold under the brand name Tepezza, is a medication used to treat thyroid eye disease (Graves' eye disease), a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to bulge outwards. It is a human monoclonal antibody developed by Genmab and Roche for tumor treatment but was later developed by River Vision Development Corporation and Horizon Therapeutics to be used for ophthalmic uses. It binds to IGF-1R. The most common side effects are muscle spasm, nausea, hair loss, diarrhea, fatigue, high blood sugar, hearing loss, dry skin, altered sense of taste, and headache. Teprotumumab should not be used if pregnant. Teprotumumab was approved for medical use in the United States in January 2020. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Sources: en.wikipedia.org
2° being the center (Bolivia) weakened by the forces of both (Argentina and Peru)". The first indications of this policy for the domain of the South Pacific occurred in the Conquest of Chiloé. After the first Chilean attempt to annex the archipelago failed, Simón Bolívar (Peru's dictator at the time), eager to curry favor with the Peruvian elite, began to consider sending an expedition to bring it under the sovereignty of Lima, based on the uti possidetis iuris (because Chiloé was under the direct administration of the Viceroyalty of Peru, and then, to this republic corresponded the territory), before Spain negotiated and ceded the island potentially to the United Kingdom or France, powers that were known to be interested in that territory, or the Chilotas attempted an expedition to some region of the South Pacific. For the Chilean government, having Bolivarian troops to the south and north (in 1825, after the occupation of Upper Peru, the forces of Bolívar went on to seize all the territory north of the Loa) was considered a threat to their sovereignty. For the same reason, Bolívar's offer to form a joint expedition that would include 2,000 Colombian soldiers was rejected. Finally, the ruler of Colombia and Peru would demand that the Freire government end the threat that royalist Chiloé posed to South America or annex it to Peru (Bolivar was willing to renounce Peruvian claims to the territory to avoid strengthening Peru economically).
== Mechanotaxis in development == Cell migration is essential in early embryonic development, as a defining characteristic of this phase is the folding and reorganization of the embryo that occurs during and after gastrulation. Without cell migration, complex structures involving multiple cell types that make up complex organisms – like tissues, organs, limbs, etc. – would not develop correctly. There are multiple factors that influence cells to move during development –– but the factors that influence mechanotaxis in development often involve interactions between cells or between a cell and a substrate such as a yolk or membrane. Contact inhibition of locomotion is involved in the migration of many cell types, including neural crest (NC) cells in vertebrates which give rise to cells of the peripheral nervous system (PNS), facial cartilage, and other non-neural cells throughout the body. NC cells are very mobile, with actin-rich protrusions at the leading edge of each cell in the direction of travel. When an NC cell collides with another NC cell, activation of the Wnt planar cell polarity (PCP) signaling pathway occurs at the point of cell contact, causing localized activation of the downstream effector RhoA. This activation is likely caused by interactions between cadherins on the cell surfaces, and leads to the retraction of the cell protrusions and a change in the cell's polarity, causing the NC cell to change direction.
In 1992, the owner of all Tim Hortons and Wendy's restaurants in Prince Edward Island, Daniel P. Murphy, decided to open new franchise outlets for both brands in the same building in the town of Montague. Murphy invited Joyce and Wendy's chairman Dave Thomas to the grand opening of the "combo store," where the two executives met for the first time. Murphy's success with combining coffee and donuts with Wendy's fast food led to the August 8, 1995, acquisition of and merger with TDL Group by Wendy's International, Inc., an American company; this lasted until 2009. The sale was widely commented on in the media. In 1995, the Toronto Star had a column reflecting on Tim Hortons "selling out" to Wendy's with "the spectacle of another great Canadian icon...gone to Yankee burgerfat".
On January 3, 2026, the United States launched airstrikes in Venezuela, capturing Venezuelan president Nicolás Maduro and his wife, and resulting in an estimated 80 casualties, including Maduro's personal guard, military personnel, and civilians. The airstrike was done without congressional awareness or authorization, resulting in criticism from media and a number of congressmen. Maduro and his wife were arraigned in a Manhattan federal court on 5, January 2026. Both pleaded not guilty to a number of drug trafficking charges. Followed by a purge of Maduro-era loyalists from the Venezuelan government, which was taken over by Delcy Rodríguez. Since 2026, Venezuela has been a de facto puppet state of the United States. The Trump administration, primarily through U.S. Secretary of State Marco Rubio, maintains control over its domestic finances, foreign policy, government appointments, revenues, and oil reserves.
== NIH Clinical Center == The National Institutes of Health Clinical Center, the world's largest hospital entirely devoted to clinical research, is a national resource that enables the rapid translation of scientific observations and laboratory discoveries into new approaches for diagnosing, treating and preventing disease. Due to its position on the main campus in Bethesda, Maryland, the Institutes and Centers of the IRP are able to mobilize clinical resources quickly and effectively to respond to emerging scientific challenges and opportunities. The NIH Clinical Center is the 2011 recipient of the Lasker-Bloomberg Public Service Award, given by the Albert and Mary Lasker Foundation. This award honors the Clinical Center for serving as a model institution that has, since 1953, transformed scientific advances into innovative therapies and provided high-quality care to patients and recognizes the Clinical Center's rich history of medical discovery through clinical research. At the NIH Clinical Center, clinical research participants—more than 480,000 since the hospital opened in 1953—are active partners in medical discovery.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.